AnaptysBio
ANAB
119 hedge funds and large institutions have $659M invested in AnaptysBio in 2023 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 31 increasing their positions, 44 reducing their positions, and 13 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
21% more capital invested
Capital invested by funds: $545M → $659M (+$115M)
3% more funds holding
Funds holding: 116 → 119 (+3)
1.61% more ownership
Funds ownership: 114.2% → 115.81% (+1.6%)
7% more call options, than puts
Call options by funds: $1.28M | Put options by funds: $1.2M
30% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 44
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$19.4M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$11.9M |
| 3 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$7.7M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$6.11M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$4.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
B
Braidwell
Stamford,
Connecticut
|
-$18.9M |
| 2 |
State Street
Boston,
Massachusetts
|
-$8.43M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$5.57M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$2.95M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$2.15M |
ANAB Hedge Fund Activity: Q4 2023 in Review
119 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q4 2023, worth a combined $659M — up 21% from $545M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new ANAB positions and 13 closed out — a net gain of 3 holders — while 31 added to existing stakes and 44 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $19.4M. The largest seller was Braidwell, exiting entirely with an estimated $18.9M sold.
- 119 institutional investors held AnaptysBio (ANAB) as of Q4 2023, up from 116 in Q3 2023.
- Funds reported $659M of AnaptysBio stock for Q4 2023, up 21% quarter-over-quarter.
- 16 funds opened new AnaptysBio positions in Q4 2023 and 13 closed out, a net change of +3 holders.
- The largest AnaptysBio buyer in Q4 2023 was Morgan Stanley, an estimated $19.4M added.
- The largest AnaptysBio seller in Q4 2023 was Braidwell, an estimated $18.9M sold.
Based on aggregated 13F filings for Q4 2023.